viewSabien Technology Group PLC

Sabien Technology - Update re. Suspension

RNS Number : 0940U
Sabien Technology Group PLC
27 July 2020

27 July 2020

Sabien Technology Group plc

("Sabien" or the "Company")

Update re. Suspension


Following the announcement on 20 January 2020 regarding the possible acquisition of Ptarmigan Health Destinations SA, the Company's shares were suspended from trading on AIM with immediate effect. This is because the transaction would be classified as a reverse takeover in accordance with the AIM Rules for Companies ("AIM Rules"). Under the AIM Rules, the Company has six months from the date of suspension to publish an admission document setting out, inter alia, details of the proposed transaction or confirm these discussions have ceased. If neither of these outcomes is achieved, trading in the Company's shares will be cancelled.


Due to market impact of Covid-19 the Company has been granted an extension from six to twelve months from 20 January 2020 for publishing such an admission document or to confirm discussions concerning a transaction have ceased.



For further information:

Sabien Technology Group plc 

Richard Parris, Chairman 


Allenby Capital Limited (Nominated Adviser)

John Depasquale / Asha Chotai 


Peterhouse Capital Limited (Broker)

Duncan Vasey/ Lucy Williams


+44 20 7993 3700



+44 203 328 5656 



+44 207 469 0930

A copy of this announcement will be available from the Company's website at www.sabien-tech.co.uk



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Sabien Technology Group PLC

Price: -

Market: AIM
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


2 min read